Skip to search formSkip to main contentSkip to account menu

S-649266

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cephalosporins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Faculty Opinions recommendation of Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
  • Richard Watkins
  • Faculty Opinions – Post-Publication Peer Review…
  • 2019
  • Corpus ID: 86629190
2018
2018
1351. In vitro Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, Against Enterobacteriaceae With Defined Extended-Spectrum Β-Lactamases and Carbapenemases
Abstract Background Cefiderocol is a novel siderophore cephalosporin targeted for activity against carbapenem and multidrug… 
2017
2017
Cefiderocol (S-649266)
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline… 
2016
2016
In Vitro Antibacterial Activity of S-649266 against Gram-negative Clinical Strains Collected in North America and Europe, 2015
Review
2015
Review
2015
Antibiotic Development and the Evolving Role of Pharmacodynamics — As Good as It Gets?
2014
2014
252S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria
Background. S-649266 (’266) is a novel catechol-substituted siderophore cephalosporin for injection discovered by Shionogi and Co… 
2014
2014
256S-649266, a Novel Siderophore Cephalosporin: Mechanisms of enhanced activity and beta-lactamase stability
256. S-649266, a Novel Siderophore Cephalosporin: Mechanisms of enhanced activity and beta-lactamase stability Masakatsu Tsuji… 
2014
2014
S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria including Multidrug-Resistant Strains
2013
2013
Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors.
To obtain a status of a medicinal product, a compound possessing potential antimicrobial activity and displaying no cytotoxicity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)